Largest health care pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 health care pharmaceutical companies ranked by revenue, at CHF 79.4B, ahead of Eli Lilly (CHF 54.9B) and Merck & Co (CHF 54.8B). Figures as of 20 Nov 2026, 03:16 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonCHF 79.4B
- Median
- CHF 2.7B
- Combined market value
- CHF 4.18T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | CHF 79.4B | CHF 541.9B | CHF 225.09 | 2.04% down | 34% up | ||
| 2 | Eli LillyLLY · Health Care | CHF 54.9B | CHF 1.01T | CHF 1,138.44 | 2.29% down | 33% up | ||
| 3 | Merck & CoMRK · Health Care | CHF 54.8B | CHF 275.9B | CHF 111.90 | 3.61% down | 45% up | ||
| 4 | PfizerPFE · Health Care | CHF 52.7B | CHF 132.3B | CHF 23.20 | 1.85% down | 15% up | ||
| 5 | AbbVieABBV · Health Care | CHF 51.5B | CHF 422.3B | CHF 238.91 | 0.86% down | 25% up | ||
| 6 | AstraZenecaAZN · Health Care | CHF 49.5B | CHF 229.2B | CHF 147.80 | 1.87% down | 1% up | ||
| 7 | NovartisNVS · Health Care | CHF 45.9B | CHF 240.6B | CHF 127.42 | 2.57% down | 25% up | ||
| 8 | SanofiSNY · Health Care | CHF 40.8B | CHF 93.2B | CHF 38.81 | 2.25% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | CHF 40.6B | CHF 100.5B | CHF 49.16 | 2.05% down | 30% up | ||
| 10 | Novo NordiskNVO · Health Care | CHF 38.6B | CHF 144.3B | CHF 32.75 | 1.42% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | CHF 37.4B | CHF 151.6B | CHF 87.52 | 0.58% down | 16% down | ||
| 12 | GSKGSK · Health Care | CHF 36.5B | CHF 80.8B | CHF 40.29 | 1.56% down | 5% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | CHF 23.8B | CHF 57.6B | CHF 18.04 | 0.66% up | 51% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | CHF 14.5B | CHF 37.9B | CHF 32.47 | 8.74% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | CHF 12.1B | CHF 80.5B | CHF 778.00 | 2.35% down | 28% up | ||
| 16 | ViatrisVTRS · Health Care | CHF 12B | CHF 19.2B | CHF 16.75 | 1.97% down | 99% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | CHF 10.1B | CHF 111.2B | CHF 438.70 | 2.94% down | 27% up | ||
| 18 | ZoetisZTS · Health Care | CHF 8B | CHF 27.7B | CHF 68.07 | 5.59% down | 26% down | ||
| 19 | GrifolsGRFS · Health Care | CHF 7B | CHF 4.7B | CHF 6.91 | 3.19% down | 0% up | ||
| 20 | BeOne MedicinesONC · Health Care | CHF 4.5B | CHF 38.5B | CHF 336.78 | 0.97% down | 16% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | CHF 4B | CHF 11.1B | CHF 22.15 | 1.54% down | 26% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | CHF 3.6B | CHF 12.8B | CHF 199.23 | 4.57% down | 41% up | ||
| 23 | GenmabGMAB · Health Care | CHF 3.1B | CHF 26.7B | CHF 43.27 | 0.75% up | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | CHF 3.1B | CHF 16.7B | CHF 124.55 | 1.06% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | CHF 3B | CHF 10.4B | CHF 12.50 | 1.00% down | 8% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | CHF 2.7B | CHF 10B | CHF 51.75 | 0.02% down | 17% up | ||
| 27 | United TherapeuticsUTHR · Health Care | CHF 2.7B | CHF 20.1B | CHF 471.09 | 3.16% down | 22% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | CHF 2.5B | CHF 6.3B | CHF 18.02 | 2.24% down | 90% up | ||
| 29 | Royalty PharmaRPRX · Health Care | CHF 2B | CHF 32.8B | CHF 57.06 | 1.38% down | 79% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | CHF 1.5B | CHF 4.1B | CHF 49.14 | 3.16% down | 21% down | ||
| 31 | AlkermesALKS · Health Care | CHF 1.2B | CHF 6.5B | CHF 38.91 | 1.43% down | 66% up | ||
| 32 | Legend BiotechLEGN · Health Care | CHF 866.9M | CHF 2.6B | CHF 13.57 | 0.92% down | 41% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 807.5M | CHF 7.8B | CHF 334.29 | 0.34% down | 27% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | CHF 795.2M | CHF 3.8B | CHF 22.94 | 0.62% down | 63% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 698.9M | CHF 5.2B | CHF 36.78 | 1.25% up | 13% up | ||
| 36 | Ascendis PharmaASND · Health Care | CHF 673.2M | CHF 14.1B | CHF 215.67 | 5.32% down | 29% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | CHF 641.6M | CHF 6B | CHF 54.75 | 4.15% down | 10% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CHF 570.9M | CHF 6.2B | CHF 78.81 | 1.59% down | 129% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | CHF 538M | CHF 6B | CHF 114.32 | 1.25% up | 6% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | CHF 519.3M | CHF 8.3B | CHF 54.67 | 1.88% down | 117% up | ||
| 41 | InsmedINSM · Health Care | CHF 511M | CHF 26.7B | CHF 121.72 | 20.58% up | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | CHF 439.3M | CHF 5.3B | CHF 80.48 | 3.27% up | 34% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | CHF 423M | CHF 12.8B | CHF 65.87 | 0.22% up | 21% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | CHF 413.5M | CHF 3.9B | CHF 40.70 | 3.86% down | 45% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | CHF 225.9M | CHF 4.8B | CHF 241.77 | 3.94% down | 50% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 159.9M | CHF 6.8B | CHF 98.41 | 1.88% down | 18% up | ||
| 47 | CytokineticsCYTK · Health Care | CHF 74.2M | CHF 6B | CHF 43.36 | 0.27% up | 19% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | CHF 38.8M | CHF 6.8B | CHF 104.50 | 2.47% down | 51% up | ||
| 49 | Roivant SciencesROIV · Health Care | CHF 7M | CHF 23.8B | CHF 32.83 | 0.59% up | 91% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | CHF 1.7M | CHF 4B | CHF 71.48 | 1.01% up | 108% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | CHF 0 | CHF 7.8B | CHF 82.26 | 3.77% down | 332% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | CHF 0 | CHF 7.3B | CHF 261.96 | 1.87% up | 86% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8426 CHF). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies rank first by revenue?
Johnson & Johnson (CHF 79.4B), Eli Lilly (CHF 54.9B) and Merck & Co (CHF 54.8B) are the top three of the 52 health care pharmaceutical companies ranked by revenue as of 20 Nov 2026, 03:16 UTC.
How many health care pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 52 health care pharmaceutical companies ranked by revenue have a combined market value of CHF 4.18T as of 20 Nov 2026, 03:16 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest health care pharmaceutical companies by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.